Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date - sprookjes - yvandenbroek - TriplyDB

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date

http://www.wikidata.org/entity/Q27004490

about

Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.Antidepressant actions of ketamine: from molecular mechanisms to clinical practice Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?A brief history of the development of antidepressant drugs: from monoamines to glutamate Homer1/mGluR5 activity moderates vulnerability to chronic social stress The role of ventral striatal cAMP signaling in stress-induced behaviors.Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology review Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder Epigenetic Activation of ASCT2 in the Hippocampus Contributes to Depression-Like Behavior by Regulating D-Serine in Mice.Increased Glutamate in Somatosensory Cortex in Functional Dyspepsia The Emerging Role for Zinc in Depression and Psychosis.Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects.Antidepressant effect of ketamine in sub anaesthetic doses in male albino mice Microglial dysregulation in psychiatric disease Neuronal nitric oxide synthase (NOS1) polymorphisms interact with financial hardship to affect depression risk Beyond serotonin: newer antidepressants in the future.Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes.Transcutaneous auricular vagus nerve stimulation triggers melatonin secretion and is antidepressive in Zucker diabetic fatty rats Evidence for alterations of the glial syncytial function in major depressive disorder.Screening for AMPA receptor auxiliary subunit specific modulators.Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression Understanding resilience.Human biomarkers of rapid antidepressant effects Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications.Current status of ketamine and related compounds for depression Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2)GluN3A: an NMDA receptor subunit with exquisite properties and functions.Ketamine as antidepressant? Current state and future perspectives.Increased PKC activity and altered GSK3β/NMDAR function drive behavior cycling in HINT1-deficient mice: bipolarity or opposing forces.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.Leading compounds for the validation of animal models of psychopathology.Novel glutamatergic drugs for the treatment of mood disorders.Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy.NMDA antagonists under investigation for the treatment of major depressive disorder.Perisynaptic astroglial processes: dynamic processors of neuronal information.Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders.Current Evidence of Chinese Herbal Constituents with Effects on NMDA Receptor Blockade.Involvement of glutamatergic neurotransmission in the antidepressant-like effect of zinc in the chronic unpredictable stress model of depression.

P2860

Q26750021-0F2BB013-DFD2-4C58-93EE-A5D795F52A03 Q26830533-C871C282-13BE-4A4F-B37E-918A1FB7C624 Q26995879-C2541A3B-A353-49F7-B0D4-6C3D17DFA0BA Q26996411-3993073F-E895-485C-8ABA-8C2C1CCD5AD0 Q27028050-45EFE0EB-633E-4C2D-8CD8-5D0186BB0BCE Q27311111-C7BCF889-43DA-4390-A046-32471AE1C90A Q27312156-454EEBAC-54EA-4CA8-B3BB-00BED6EE9AC5 Q28067988-BDA5A2FE-C2E2-4D15-B21F-76A1A4BDEB16 Q28072353-0DE31F8D-0FEF-4A0E-B600-6BE31BA24737 Q30711088-67318988-CF92-4C63-883F-2F802D8DC84E Q33650476-45AF5A7A-085C-48C8-B5E9-C617E810AA4C Q33818965-E6370790-048C-4324-B1A1-2E753F858932 Q33857369-24416693-F961-425E-8750-281CB4D4AE45 Q33874356-91C20332-F48D-4514-81A2-F3B1CA88793E Q34030230-7587CCD9-1D56-4622-9AAE-D1EE56ADA2A8 Q34345744-D741C220-E905-4A54-A1F8-F77F2CA54656 Q34357009-FAF6291F-EAA8-42A8-AE62-093A4AEFFC78 Q34557706-2D1ED697-C701-4E40-9C41-85C1E77FABC5 Q34878452-FCC83FFD-2F79-4EFE-9BF1-39192CA94385 Q35367511-A14B0E0E-B009-468B-826E-633E47496193 Q35828185-05312D35-F7BF-49D8-AF74-555E7799CA7C Q36328451-6848813B-9BF8-4505-ACAE-54547912A50C Q36417179-A02BE325-7B9E-4CAB-B83F-C55EA343CBB1 Q36612228-56BEE2B1-E05A-4719-BCB8-71A3E908FCAB Q36902074-DB9EAA4B-2AC3-4052-9BD9-F930C91E7EBD Q37121338-47A7BC7C-04AF-4CDD-99E8-37A3700CDC02 Q37202885-DFFC3525-D0E3-44EE-9153-CB0B21D75044 Q37242260-27D3E043-82CE-4B89-9F7E-A137EA9A7FE5 Q37412890-44D40CC8-E3F7-47BF-BD96-3DBEDA3C4576 Q37559823-C20B3ACC-588F-4311-87F6-1073819E6BD7 Q37668134-7E03C0B8-DE64-412C-A160-500FF742C8A1 Q38123516-2BA662DE-A29D-41B5-9B53-9611EA420A18 Q38128733-DF0B3DD0-F49D-421E-80C8-4B1BD919FA51 Q38131480-3F9DD134-5590-4AC0-9B32-69EFF7445986 Q38157027-BEE262FD-3CF2-4394-8B49-BA4D67390F0C Q38211107-53AF041C-BCFF-4A95-B8CD-9ACE35CB3DA9 Q38508710-CBDDD24E-AEA1-4E81-86DD-E82F4034447A Q38924066-A085E4A9-E51B-428B-A200-65AE9DCD3EBD Q39307652-C0BBE15A-262D-4806-A92B-C053816798AF Q40127644-39B8C870-7F69-40E9-83CE-6EF0FEA8849C

P2860

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date

http://www.wikidata.org/entity/Q27004490

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Targeting the glutamatergic sy ...... rationale and progress to date

@ast

Targeting the glutamatergic sy ...... rationale and progress to date

@en

Targeting the glutamatergic sy ...... rationale and progress to date

@nl

type

label

Targeting the glutamatergic sy ...... rationale and progress to date

@ast

Targeting the glutamatergic sy ...... rationale and progress to date

@en

Targeting the glutamatergic sy ...... rationale and progress to date

@nl

prefLabel

Targeting the glutamatergic sy ...... rationale and progress to date

@ast

Targeting the glutamatergic sy ...... rationale and progress to date

@en

Targeting the glutamatergic sy ...... rationale and progress to date

@nl

P1433

Q27004490-48E35147-6DE9-4C74-B6E5-3C5188995055

P1476

Q27004490-1AB0593B-5BB7-406D-ADE6-3E97C6613237

P2093

Q27004490-1F2F49E2-7DE7-4B49-B61B-5215F218CCEF

Q27004490-AAF0E2C9-F6C3-4638-B1D4-7095D07A6E83

P2860

Q27004490-0157FC92-F311-4B37-8691-8133632AD83E

Q27004490-02058259-4A3A-4142-99CD-7347CA979E85

Q27004490-021EF999-795B-4977-BB5B-59A2B87D9DE3

Q27004490-02323E2C-EF70-40F0-99A3-E22A285D877D

Q27004490-02D9BC7F-0DF9-46EE-8C0C-CC283BC855CD

Q27004490-0365A965-C28F-46CA-AAC4-FBCD424E30E8

Q27004490-05391689-B4F6-40B0-80E9-87E007A6C317

Q27004490-0648622E-1A44-4362-8E9C-E16B7C396BFC

Q27004490-08577585-EAAA-495A-9D3D-8B51B4EF43E4

Q27004490-0859E8C2-B352-44BC-8525-AC67C7220A85

P2888

Q27004490-6004168F-1C2D-45FC-A5D3-43C2438D959F

P304

Q27004490-70C0E7C1-9B4B-477A-9F37-AE185A7FE806

P31

Q27004490-BB5F41E4-6A0B-4073-9634-3F50EB703A86

P3181

Q27004490-8F41DF82-03E4-48A9-B820-2B8644032EC9

P356

Q27004490-044EEB6C-89AB-4855-964C-01356C44DAF4

P407

Q27004490-FD3F41BF-4BDA-4A91-8F18-AE274EBDDD09

P433

Q27004490-6E399E74-D36B-4ADA-A02E-01FD9930AFA1

P478

Q27004490-6A42A321-7CC2-4115-8025-61C1A1CB0432

P50

Q27004490-70014BDF-7413-4E69-94FC-E3DE452590B3

P577

Q27004490-F01A3BD6-218F-415F-B656-8A758AD934EA

P5875

Q27004490-2D8EED22-064A-4046-89F5-04AE14E18EB8

P6179

Q27004490-2F80B9BB-6573-442E-8909-01805D22E1D9

P698

Q27004490-3E5B594C-3D3B-43A2-85CC-BA2ABDCC368F

P932

Q27004490-FF9F3DB7-9985-49F7-9EFD-E1928FF7CFB7

P3181

P356

11633130-000000000-00000

P1433

P1476

Targeting the glutamatergic sy ...... rationale and progress to date

@en

P2093

Carlos A Zarate

http://www.w3.org/2001/XMLSchema#string

Daniel C Mathews

http://www.w3.org/2001/XMLSchema#string

P2860

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials

The catecholamine hypothesis of affective disorders: a review of supporting evidence

Glycogen synthase kinase 3: more than a namesake

A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders

mTOR signaling: at the crossroads of plasticity, memory and disease

The glutamate story

P2888

11633130-000000000-00000

P304

1313-1333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3437460

http://www.w3.org/2001/XMLSchema#string

P356

10.2165/11633130-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228065239

http://www.w3.org/2001/XMLSchema#string

P6179

1046184655

http://www.w3.org/2001/XMLSchema#string

P698

22731961

http://www.w3.org/2001/XMLSchema#string

P932

3439647

http://www.w3.org/2001/XMLSchema#string